New hope for rare breast cancer? trial of taletrectinib underway
NCT ID NCT06214793
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing the drug taletrectinib in people with a rare, advanced form of breast cancer called invasive lobular carcinoma that has a specific gene change (CDH1 mutation). The study aims to see if the drug can shrink tumors or slow the cancer's growth. The trial is currently suspended and plans to enroll about 61 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Taletrectinib (a targeted oral drug)
What this could lead to
If it works, this could point toward a new treatment option for a rare, hard-to-treat form of breast cancer.
What could go wrong
The trial is small (61 people) and currently suspended, so results may be delayed or never come. It is also only for patients with a specific gene mutation, so it would not help most breast cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
-
Marone Cancer Center Cleveland Clinic Florida
Weston, Florida, 33331, United States